entecavir

(redirected from Baraclude)
Also found in: Medical.
Related to Baraclude: hepatitis B
Translations

entecavir

n entecavir m
References in periodicals archive ?
Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed.
In 2011, only two blockbusters existed in the market - Baraclude for treating hepatitis B and Incivek for treating hepatitis C.
A spokeswoman for Bristol-Myers Squibb said that a "Dear Healthcare Provider" letter has been issued suggesting "caution" when prescribing entecavir, marketed as Baraclude, to patients coinfected with HIV and hepatitis B virus (HBV) when they are not simultaneously receiving anti-HIV therapy.
Tokyo, Japan, Aug 3, 2006 - (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry.
BMS will market entecavir under the trade name Baraclude.
announced on November 10 that the Ministry of Health, Labor and Welfare has granted the company with a priority review status for BARACLUDE Tablet, an agent for treating chronic hepatitis B virus (HBV) infection, as of November 8.
BARACLUDE is currently indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in aminotransferases (ALT or AST), or histologically active disease.
Entecavir, first approved by the FDA in 2005 for treating chronic hepatitis B in adults with compensated liver disease, is marketed as Baraclude by BMS.
Daniels directed the development of innovative medicines, including: apixaban, Onglyza (saxagliptin), Myalept(TM) (metreleptin for injection), and Farxiga(TM) (dapagliflozin), in CV/metabolics; Orencia (abatacept) and Nulojix (belatacept), in immunology; Abilify (aripiprazole), in neuroscience; Baraclude (entecavir), Reyataz (atazanavir), daclatasvir, and asunaprevir, in virology; and Sprycel (dasatinib), Ixempra (ixabepilone), Yervoy (ipilimumab), elotuzumab, and nivolumab, in oncology.
Contract award: delivery - medicines, infusion solutions, nutrition formulations, preparations, diagnostic contrast, preparations for the treatment of chronic hepatitis - type c and baraclude